Skip to main navigation
Skip to search
Skip to main content
Maastricht University Home
Support & FAQ
Link opens in a new tab
Search content at Maastricht University
Home
Researchers
Publications
Activities
Press/Media
Prizes
Organisations
Dataset/Software
Projects
A reappraisal of generic bisphosphonates in osteoporosis
John A. Kanis
*
, J.Y. Reginster
, Jean-Marc Kaufman
, J.D. Ringe
, J.D. Adachi
,
M. Hiligsmann
, R. Rizzoli
, C. Cooper
*
Corresponding author for this work
Health Services Research
CAPHRI - Care and Public Health Research Institute
Research output
:
Contribution to journal
›
Article
›
Academic
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'A reappraisal of generic bisphosphonates in osteoporosis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Bisphosphonates
100%
Osteoporosis
100%
Poor Adherence
50%
Treatment Efficacy
25%
Cost-effectiveness
25%
Practice Guidelines
25%
Generic Drugs
25%
Bioequivalence
25%
Particulate Matter
25%
Guideline Development
25%
Osteoporosis Treatment
25%
Alendronate
25%
Development Cost
25%
Cost Impact
25%
Competitive Price
25%
Rapid Disintegration
25%
Esophageal mucosa
25%
Formal Testing
25%
Market Authorization
25%
Disintegration Time
25%
Treatment Impact
25%
Disease Burden
25%
Generic Formulation
25%
INIS
osteoporosis
100%
reviews
66%
guidelines
66%
testing
33%
diseases
33%
increasing
33%
safety
33%
cost
33%
mucosa
33%
management
33%
esophagus
33%
market
33%
prices
33%
particulates
33%
Nursing and Health Professions
Bisphosphonic Acid Derivative
100%
Practice Guideline
50%
Cost Effectiveness Analysis
25%
Literature Review
25%
Disease Burden
25%
Alendronic Acid
25%
Bioequivalence
25%
Pharmacology, Toxicology and Pharmaceutical Science
Bisphosphonic Acid Derivative
100%
Bioequivalence
25%
Alendronic Acid
25%
Diseases
25%